XML 33 R12.htm IDEA: XBRL DOCUMENT
v3.20.4

Goodwill and Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | NOTE D – GOODWILL AND OTHER INTANGIBLE ASSETS The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
| As of December 31, 2020 |  | As of December 31, 2019
(in millions) | Gross Carrying Amount |  | Accumulated Amortization/Goodwill Impairment Charges |  | Gross Carrying Amount |  | Accumulated Amortization/Goodwill Impairment Charges
Technology-related | $ | 11,059 |  |  | $ | (6,179) |  |  | $ | 12,020 |  |  | $ | (5,706) |
Patents | 511 |  |  | (407) |  |  | 525 |  |  | (408) |
Other intangible assets | 1,775 |  |  | (1,220) |  |  | 1,754 |  |  | (1,081) |
Amortizable intangible assets | $ | 13,345 |  |  | $ | (7,806) |  |  | $ | 14,299 |  |  | $ | (7,195) |
Goodwill | $ | 19,924 |  |  | $ | (9,973) |  |  | $ | 20,076 |  |  | $ | (9,900) |
IPR&D | 257 |  |  |  |  | 662 |  |  |
Technology-related | 120 |  |  |  |  | 120 |  |  |
Indefinite-lived intangible assets | $ | 377 |  |  |  |  | $ | 782 |  |  |
During 2020, following receipt of regulatory approvals, we reclassified certain of our IPR&D intangible assets to amortizable technology-related assets and began amortization to reflect their use over their remaining lives. Intangible asset impairment charges were $460 million in 2020, $105 million in 2019 and $35 million in 2018. The impairment charges recorded in 2020 were primarily associated with our acquisitions of Apama Medical Inc. and nVision Medical Corporation (nVision) following management’s decision to cancel the programs due to cost to complete, time to market, overall economic viability or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology. Intangible asset impairment charges in 2020 also included charges related to our acquisition of Sadra Medical, Inc. (Sadra Medical) as a result of lower sales forecasts, as well as the cost of quality remediation efforts following the voluntary recall of our LOTUS Edge™ Aortic Valve System and subsequent discontinuation of the LOTUS platform. The following represents our goodwill balance by global reportable segment and our separately presented Specialty Pharmaceuticals operating segment:
(in millions) | MedSurg |  | Rhythm and Neuro |  | Cardiovascular |  | Specialty Pharmaceuticals |  | Total
Balance as of December 31, 2018 | $ | 2,063 |  |  | $ | 1,924 |  |  | $ | 3,925 |  |  | $ | — |  |  | $ | 7,911 |
Foreign currency fluctuations and other changes | (1) |  |  | — |  |  | 58 |  |  | 9 |  |  | 66 |
Goodwill acquired | — |  |  | 268 |  |  | 1,712 |  |  | 238 |  |  | 2,218 |
Goodwill divested | — |  |  | — |  |  | (19) |  |  | — |  |  | (19) |
Balance as of December 31, 2019 | $ | 2,061 |  |  | $ | 2,192 |  |  | $ | 5,676 |  |  | $ | 247 |  |  | $ | 10,176 |
Foreign currency fluctuations and other changes | (2) |  |  | 3 |  |  | 22 |  |  | — |  |  | 22 |
Goodwill impairment charges | — |  |  | — |  |  | — |  |  | (73) |  |  | (73) |
Goodwill reclassified to Current assets held for sale | — |  |  | — |  |  | — |  |  | (175) |  |  | (175) |
Balance as of December 31, 2020 | $ | 2,059 |  |  | $ | 2,194 |  |  | $ | 5,697 |  |  | $ | — |  |  | $ | 9,951 |
In 2020, we recorded Goodwill impairment charges of $73 million related to our Specialty Pharmaceuticals business. We did not record any Goodwill impairment charges in 2019 or 2018. Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing. Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2020 is as follows (in millions):
Fiscal Year |
2021 | $ | 689 |
2022 | 664 |
2023 | 651 |
2024 | 613 |
2025 | 560 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration